A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer Associated Anorexia

January 19, 2022

Protocol: Alliance – A222004

SCHEMA A222004

Please Note: Below is partial eligibility, for full eligibility requirements, please contact GHCI Research Department at (810)762-8181, (810)762-8079 and/or (810)762-8038. Thank you!


  1. Diagnosis of advanced cancer.
  2. Patient report 2 month weight loss of at least 5 pounds (2.3 kilograms) and/or physician estimated caloric intake of less than 20 calories/kilogram of body weight per day.
  3. The patient must perceive loss of appetite and/or weight as a problem, and have an appetite score of 4 or worse on the “Please rate your specific appetite” question that requires a patient response on a 0-10 numeric rating scale.
  4. Not receiving ongoing tube feedings or parenteral nutrition at the time of registration.
  5. Not currently using systemic adrenal steroids (with the exception of short term dexamethasone within 3 days of chemotherapy for control of chemotherapy side effects).
  6. No use of androgens, progesterone analogs, or other appetite stimulants withint he past month.
  7. No Covid-19 infection in the past hat, in the opinion of the treating physician, had left patients with compromised taste, which has not resolved at the time of registration.
  8. At least 18 years of age.
  9. Estimated life expectancy of 3 months or longer.
  10. No treatment with another antipsychotic agent, such as risperidone, quetiapine, clozapine, butyrophenone within 30 days of enrollment.

Genesys Hurley Cancer Institute

302 Kensington Avenue (Print a Map)
Flint, MI 48503

810-762-8226 | 888-762-8675

Ascension Genesys Hospital
Hurley Medical Center
Michigan Cancer Consortium


Ⓒ 2020 Genesys Hurley Cancer Institute | All Rights Reserved.